CLOPERASTINE

First approved in 2018

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H24ClNO
Molecular Weight	329.864
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC=C(C=C1)C(OCCN2CCCCC2)C3=CC=CC=C3

InChI

InChIKey=FLNXBVJLPJNOSI-UHFFFAOYSA-N

InChI=1S/C20H24ClNO/c21-19-11-9-18(10-12-19)20(17-7-3-1-4-8-17)23-16-15-22-13-5-2-6-14-22/h1,3-4,7-12,20H,2,5-6,13-16H2

HIDE SMILES / InChI

Molecular Formula	C20H24ClNO
Molecular Weight	329.864
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21445282

Cloperastine (INN) or cloperastin is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, and in some European countries. It was first introduced in 1972 in Japan, and then in Italy in 1981. The precise mechanism of action of cloperastine is not fully clear, but several different biological activities have been identified for the drug, of which include: ligand of the gamma1 receptor (Ki = 20 nM) (likely an agonist), GIRK channel blocker (described as "potent"), antihistamine (Ki = 3.8 nM for the H1 receptor), and anticholinergic. Cloperastine possesses dual activity. It also acts as a mild bronchorelaxant and has antihistaminic activity, without acting on the central nervous system or the respiratory center.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cough 106 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20460867	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Cloperastine rescues impairment of passive avoidance response in mice prenatally exposed to diethylstilbestrol.	2014-02	22223406
Cloperastine-based cough syrup and acute dystonic reactions.	2012-03	22324643
[Novel antidepressant-like action of drugs possessing GIRK channel blocking action in rats].	2010-05	20460867
Simultaneous quantitation of paracetamol, caffeine, pseudoephedrine, chlorpheniramine and cloperastine in human plasma by liquid chromatography-tandem mass spectrometry.	2010-02-05	19879084
Ameliorating effects of cloperastine on dysfunction of the urinary bladder caused by cerebral infarction in conscious rats.	2009-11	19935896
Effects of solid-state reaction between paracetamol and cloperastine hydrochloride on the pharmaceutical properties of their preparations.	2007-04-20	17118591
Simultaneous determination of ten antihistamine drugs in human plasma using pipette tip solid-phase extraction and gas chromatography/mass spectrometry.	2006	16419026
Levocloperastine in the treatment of chronic nonproductive cough: comparative efficacy versus standard antitussive agents.	2004	15553659

Patents

Sample Use Guides

In Vivo Use Guide

10–20 mg three times daily for adults

Route of Administration: Oral

In Vitro Use Guide

Cloperastine inhibited the hERG K⁺ channels, expressed in HEK293 cells, in a concentration-dependent manner with an IC₅₀ value of 0.027 μM

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:21:00 GMT 2025` Edited by `admin` on `Wed Apr 02 08:21:00 GMT 2025`
Record UNII	69M5L7BXEK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLOPERASTINE

Official Name

English

CLOPERASTINE [MI]

Preferred Name

English

CLOPERASTINE [MART.]

Common Name

English

cloperastine [INN]

Common Name

English

HT-11

Code

English

1-(2-((P-CHLORO-.ALPHA.-PHENYLBENZYL)OXY)ETHYL)PIPERIDINE

Common Name

English

NSC-758635

Code

English

Cloperastine [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

R05DB21